Peritoneal Dialysis Guideline



Tuberculosis Screening & Follow-Up

Contents

1.0	Scope of Guideline	
2.0		
3.0		
4.0		
5.0		
6.0		
7.0		
	Appendix 1: BC TB Screening Workflow for Renal Patients	
	Appendix 2: TB Screening Questionnaire in PROMIS	
	Appendix 3: IGRA Lab Requisition in PROMIS	
	Appendix 4: Chest X-Ray Requisition in PROMIS	
	Appendix 5: Distribution of Reports/Letters & Follow Up of Results	
	Appendix 6: Samples of Follow-Up Reports/Letters	
, ,	Letter 1: Non-Reactive IGRA Results	
	Letter 2: Reactive IGRA Results (Latent TB Infection)	
	Letter 2. Redetive rong negatio (Laterit 10 infection)	L.

1.0 Scope of Guideline

This guideline provides tuberculosis (TB) screening and follow-up recommendations and procedures for incident (new to dialysis) adult peritoneal dialysis patients.

The guideline is applicable to all new Peritoneal Dialysis (PD) patients attending training at the regional PD outpatient units in British Columbia.

Refer to Appendix 1 for an overview of the TB Screening & Follow-Up Workflow.



2.0 Summary of the Literature & Internet

Tuberculosis (TB) is a disease caused by the bacteria *Mycobacterium tuberculosis* that is spread from person to person through droplets in the air. TB usually affects the lungs, but it can also affect other parts of the body, such as lymph nodes, the brain, kidneys or the spine.

M. tuberculosis can exist in an active or latent state in the human body:

- 1. Active TB, also called TB disease, is usually symptomatic and often transmissible. With active TB, tests for TB bacteria are usually positive and radiologic tests may be abnormal.
- 2. Latent TB infection (LTBI), also called TB infection, is the presence of latent or dormant TB bacteria in the body but no evidence of active TB. This means that the person does not have TB symptoms, there is no evidence of radiographic changes consistent with active TB and microbiologic tests are negative. LTBI is not infectious; however, if left untreated, healthy persons diagnosed with LTBI have a 5-10% lifetime risk of progressing to active TB. This percentage increases significantly when additional risk factors exist, such as end-stage kidney disease, with cited relative risks ranging from 7 50 times the background incidence (Canadian TB Standards, 7th Edition, 2014).

This guideline provides recommendations aimed at reducing the incidence of active TB in the chronic kidney disease (CKD) population in BC through incident screening and identification and treatment of dialysis patients with LTBI. Treatment of patients with LTBI will reduce the number of active TB cases in the dialysis population, avoiding time and labour-intensive contact follow-up. Fewer active cases will, in turn, reduce transmission of TB within the larger CKD population.

The TB screening program recommended for dialysis patients in this guideline includes 3 components:

- 1. TB screening questionnaire
- 2. Chest radiography (x-ray)
- 3. Interferon Gamma Release Assays (IGRA)
 - IGRAs are immunological tests that are (1) not influenced by prior BCG vaccine or exposure to most nontuberculous mycobacteria; and (2) are more robust that Tuberculin skin Test (TST) in their performance in immunocompromised patients (including those on dialysis) (BCCDC, 2019).
 - The traditional tuberculin skin test (TST) has a high false negative rate (because of a high prevalence of anergy in dialysis patients). The IGRA is reported to be a more sensitive test than the TST in the dialysis population, while offering a comparable level of specificity. (Ferguson, 2014). Further, compared to the TST, the IGRA was associated more strongly with risk factors for LTBI in end-stage kidney disease. (Rogerson, 2013).
 - The sensitivity and specificity of testing varies depending upon the population being tested (BCCDC,2019).
 - There are two types of IGRA tests available in BC: (1) QuantiFERON®-TB Gold Plus® [QFT Plus] (Enzyme-linked Immunosorbent Assay (ELISA) on whole blood); and (2) T-SPOT® (Enzyme-linked Immunospot Assay on peripheral blood mononuclear cells). These tests



appear to have similar sensitivity and specificity, however, QFT-Plus is easier to use and less expensive. As a result, QFT-Plus is used more often in TB screening of dialysis patients in BC.

3.0 Recommendations

Recommendation #1: Screen the following patients for TB during the initial week of PD training:

- 1. All patients who start chronic dialysis (see recommendation #2 for exception)
- 2. Chronic dialysis patients who move to BC from another province/country

Recommendation #2: <u>Do not</u> rescreen patients previously screened using the BCCDC/BCR screening process (questionnaire, IGRA and chest x-ray) (see recommendation #3 for exception). This includes patients changing treatment types (e.g., PD to HD, transplant to HD, KCC to PD) regardless of the length of time since the initial screening (refer to <u>Procedure</u> section for ways to identify if previous screening was done). The BCCDC/BCR screening process started in 2016.

For patients with a previous documented IGRA test (anytime in the past) but not as part of the 3-component protocol outlined in this guideline:

- Submit the TB screening questionnaire and chest x-ray as per the 3-component protocol.
- Do not repeat the IGRA. Enter the date the IGRA was completed, and the TB Physician will advise if a more recent IGRA is required.

In general, repeat, or serial IGRA testing is not recommended. In certain circumstances, it may be appropriate, most commonly following a known TB exposure. If unclear for a specific case, contact the Nurse Consultants in TB Services (phone: BCCDC, 604.707.5678; Island Health, 250-519.1510).

Recommendation #3: For patients who received dialysis while travelling in a country where TB is endemic:

- 1. If dialysis was for less than 3 months, it is not necessary to rescreen for TB. Please be aware that the patient is at higher risk for TB and watch for symptoms.
- 2. If dialysis was for **longer than 3 months** while travelling in a country where TB is endemic (rate higher than 50/100,000 population):
 - If the baseline IGRA was **negative**, it is recommended that the nephrologist order an IGRA test. If the IGRA result is <u>reactive/positive</u>, refer patient to BCCDC via the usual TB screening process in PROMIS, including completion of the TB screening questionnaire and arranging a chest x-ray.
 - If the baseline IGRA was **positive**:
 - Do not repeat IGRA.
 - If previously treated for latent TB, nothing more is required.
 - If not previously treated for latent TB, complete TB screening questionnaire in PROMIS, arrange chest x-ray and refer to BCCDC via PROMIS. Prophylactic treatment may be rediscussed at this stage.



To identify whether TB is endemic:

- Go to the <u>World Health Organization</u> website (WHO, Data, TB data, TB country, regional and global profiles)
- Go to the green bar at the top of the page and select the country
- Review the "Total TB incidence" rate (first line). If greater than 50/100,000 population, IGRA is recommended.

Recommendation #4: Utilize the BCCDC/BCR 3-component protocol to screen for TB:

- 1. TB screening questionnaire
- 2. IGRA blood test: QFT- Plus
- 3. Chest x-ray within the past 6 months

The TB Screening Tracking Report in PROMIS shows the TB Assessment Date (completion of TB screening questionnaire), chest X-Ray order date, TB IGRA order date and the date that BCCDC was alerted (BCCDC is alerted automatically by PROMIS when the three components are completed).

TB screening questionnaire (see Appendix 2 for example)

This questionnaire is available as a fillable form in PROMIS. Print the questionnaire from PROMIS (demographics will auto populate), discuss the questions with the patient and enter the responses into PROMIS. BC Centre for Disease Control (BCCDC) will have access to the completed questionnaire, along with the results of the IGRA test and chest x-ray, in PROMIS for analysis.

IGRA testing (see Appendix 3 for example of IGRA lab requisition)

The IGRA lab requisition is available in PROMIS (demographics will auto populate). Print the requisition from PROMIS and place with the blood sample prior to sending to the laboratory. BE SURE TO USE THE IGRA LAB REQUSITION IN PROMIS and not the standard lab requisition.

IGRA blood samples may be drawn in any hospital that has been designated (trained and set up) as an *IGRA collection site* by the BCCDC Provincial Health Laboratory. See www.bccdc.ca/resource-gallery/Documents/Educational%20Materials/TB/IGRAsites.pdf (note the restricted days/hours for IGRA blood collection). Pre-analytical processing of samples is performed in any hospital that has been designated (trained and set up) as an *IGRA processing site*. Accurate results rely on specific collection methods and care of samples after the blood draw.

- If the receiving laboratory is a designated *IGRA processing site*:
 - Samples are incubated for 16-24 hours.
 - Samples are centrifuged and the plasma portion pipetted off into new vials.
 - Plasma samples are transported to the BCCDC Public Health Laboratory for analysis.
- If the receiving laboratory is *NOT* a designated *IGRA processing site*:
 - The receiving laboratory packages the samples (insulated so that the samples are maintained at room temperature).

¹ All hospitals with PD units are IGRA collection sites.



The receiving laboratory transports the samples to a designated IGRA processing site
within the HA for processing (Note: samples must be incubated within 16 hours of
collection at the designated IGRA processing site).

BCCDC will have access to the results of the IGRA test, along with the completed questionnaire and chest x-ray report, in PROMIS for analysis. The results of the IGRA tests are usually available within 1 week of the sample being drawn.

Chest x-ray (see Appendix 4 for example of chest x-ray requisition)

The chest x-ray requisition is available in PROMIS (demographics will auto populate). Print the requisition and give to the patient. BE SURE TO USE THE CHEST X-RAY REQUSITION IN PROMIS and not the standard radiology requisition.

The patient may have his/her chest x-ray at any <u>hospital</u> medical imaging department. Once the report is available, a copy will be sent by the medical imaging department to the PD unit <u>and</u> to the BCCDC (copy to the BCCDC is noted on the PROMIS requisition). BCCDC will manually upload the report into PROMIS.

If the patient has had a chest x-ray within the past 6 months, a repeat chest-ray is not required. Enter the date the x-ray was completed into PROMIS. BCCDC will manually upload the x-ray report into PROMIS. If this report/image is inconclusive, BCCDC will advise the PD unit to provide the patient with a chest x-ray requisition specific for ruling out TB.

BCCDC will have access in PROMIS to all 3 components of TB screening for analysis - the completed TB screening questionnaire, IGRA test results and the chest x-ray report.

Recommendation #5: If an IGRA result is "indeterminant" or "unsatisfactory," repeat once (if available at your site, consider T-spot instead of a second QFT). If the second result comes back indeterminant or unsatisfactory, do not repeat. The TB physician will review the file and issue a report based on the information available.

Recommendation #6: Once all 3 components in recommendation #4 have been completed, PROMIS will automatically alert BCCDC.

Once BCCDC receives the "Alert" from the renal unit, they will check PROMIS for the completed TB screening questionnaire, the IGRA blood test result and the chest x-ray report. If any of these components are missing one month after the "Alert" was sent, BCCDC will notify the patient's unit. The unit will be responsible for follow-up with the patient. If components are still missing after another 2 months, the incomplete information will be sent to the TB screening physician who will issue a report indicating incomplete results.

If the patient wishes to complete the screening in the future (e.g., when starting the transplant process), the process/referral will need to be started again at that time.



Recommendation #7: After analysis of the results, BCCDC TB Services will issue a report/letter, including recommendations.

BCCDC TB Services will manually upload the report/letter including recommendations, into PROMIS. Reports/letters will be available in PROMIS within 1 month of the three components being received by the BCCDC. To review the report/letter in PROMIS, search for the patient, go to "Documents," then filter by "TB Services Recommendations."

Distribution of the reports/letters and follow-up of results will depend upon the outcome of the testing. See Appendix 5 for an overview of report/letter distribution and follow-up for each type of result. Copies of the reports/letters for different result types are available in Appendix 6.

*For Island Health: BCCDC will fax copies of the TB screening questionnaire, IGRA blood test results and the chest x-ray report to the Island Health TB program (BCCDC will also upload a copy of the chest x-ray report into PROMIS). The Island Health TB program will analyze the results and issue a report, including recommendations. The Island Health TB Clinic will alert BCCDC TB Services of the availability of a report in Panorama. BCCDC TB Services will upload the report into PROMIS. The Island Health TB Clinic will follow up on the results with the patient/appropriate care providers.

Recommendation #8: Implement appropriate TB precautions within the PD unit as per follow-up protocols.

LBTI is not infectious, therefore, there are no specific infection control procedures required for patients diagnosed with LTBI. If active TB is identified, local facility infection control procedures should be implemented and reported to BCCDC.

4.0 Procedure

- 1. Designate a person(s) responsible for TB screening processes and to ensure the process is completed for every new PD patient (e.g., PD nurse, Patient Care Coordinator, unit clerk).
- 2. Utilize the TB Screening Tracking Report in PROMIS to track new chronic PD patients and the status of each component of TB screening:
 - Go to Reports, TB Screening.
 - Enter the dates of interest (based on start date of chronic dialysis), dialysis type and dialysis or primary management centre.
 - Click on Run.

The report will show the TB Assessment Date (completion of questionnaire), chest X-Ray order date, IGRA order date and the date that BCCDC was alerted (BCCDC is alerted automatically by PROMIS when the first three components are completed).




- 3. On admission ensure the following orders are included for new PD patients:
 - a. Complete TB screening questionnaire
 - b. IGRA blood test (QFT-Plus)
 - c. Chest x-ray within past 6 months
- 4. Once patient is registered in PROMIS, print the following documents and add to patient record (unless a previous TB screening report is on file):
 - a. Auto-populated TB screening questionnaire
 - b. Auto-populated Laboratory requisition for IGRA (QFT-Plus) blood test (unless a previous IGRA result is on file)
 - c. Auto-populated Chest x-ray requisition (unless a chest x-ray was completed within the previous 6 months)

Procedure

Component		Action	Responsibility
1 Check for previous IGRA/TB screening report		Check if patient previously screened for TB using the BCCDC/BCR screening process (questionnaire, IGRA and chest x-ray). If so, screening does not need to be repeated. To check for previous TB screening: On PROMIS 4, go to Renal > TB Assessment If the TB Screening Questionnaire Summary is blank, TB screening was not previously completed If there is a pre-existing TB Screening Questionnaire, click to open Click on or scroll down to TB Services Completes to see if there has been a TB physician review To view the TB physician narrative report: On PROMIS 4, go to Documents, filter by TB Services Recommendation TB Physician/Nurse Practitioner narratives are also automatically uploaded to CareConnect under Documents	RN/Unit Clerk
2	TB screening questionnaire See Appendix 2	After patient is registered in PROMIS, prepare questionnaire: Search for patient. Under Renal menu, select TB Services. Under TB Assessment tab, select Add: Enter assessment date. Check Population at Risk checkbox. Select Renal TB screening as the Reason for Screening. Under Risk Factors, check Chronic Renal Disease/Dialysis. Click Save.	Unit Clerk

^{*}It is important to use the forms in PROMIS that are auto-populated. DO NOT USE STANDARD LAB REQUISITIONS/CHEST X-RAY FORMS.







Component		Action	Responsibility
	TB screening questionnaire cont'd	 Enter completed Questionnaire into PROMIS: Search for patient. Under Renal menu, select TB Services. Under TB Assessment tab, select record with the corresponding Assessment Date. Select pencil icon next to Nurse Completes to edit the record. Enter information (from completed Questionnaire). Select Save. Discard hard copy of Questionnaire once entered into PROMIS 	Unit Clerk
3	Check Care Connect/PROMIS for previous IGRA test. If none, print lab requisition from PROMIS: Search for patient. Select Reports Menu (same row as the Renal menu). Select arrow next to TB Screening to view list of reports. Select IGRA QFT Requisition. Note: Primary nephrologist will show as the ordering physician — do not change. Select Run Report. Print requisition and provide to RN.		Unit Clerk
		Give requisition to patient & ask to take to lab or request lab staff come to PD unit (check with local laboratory as to limitations on days that IGRA samples can be collected). If lab staff coming to PD unit, call to inform them of IGRA test. Special blood collection and handling techniques are required.	RN/Unit clerk
		 Document that patient was provided the requisition (or lab collected blood sample) or date a previous IGRA test was completed in PROMIS: Search for patient. Under Renal menu, select TB Services. Under TB Assessment tab, select the record with the corresponding Assessment Date. Select pencil icon next to Nurse Completes to edit the record. Under IGRA test section, check IGRA Test QFT checkbox and enter IGRA Order Date. Click Save. 	RN/Unit Clerk
4	Chest x-ray See Appendix 4	 Check Care Connect for chest x-ray performed in past 6 months. If none, print requisition from PROMIS: Search for patient. Select Reports Menu (same row as the Renal menu). Select arrow next to TB Screening to view a list of reports. Select Chest X-Ray Requisition. Note: Primary nephrologist will show as the ordering physician – do not change. Under Management Centre, select PD Clinic 	Unit Clerk



Co	mponent	Action	Responsibility
	Chest x-ray	Under Unit, select PD unit	
	cont'd	Select Run Report	
		Print requisition & give to patient.	
		Instruct patient to have chest x-ray done at a hospital medical	
		imaging department during PD training week.	
		Document that patient was provided the requisition or had a chest x-	Unit Clerk
		ray completed within the past 6 months in PROMIS:	
		Search for patient.	
		Under Renal menu, select TB Services.	
		Under TB Assessment tab, select the record with the	
		corresponding Assessment Date.	
		Select pencil icon next to Nurse Completes to edit the record.	
		Under Chest X-Ray section, enter Order Date.	
		Click Save.	
		BCCDC will review results and upload into PROMIS.	
5	BCCDC will be Once all 3 components have been completed, PROMIS will		PROMIS
	notified	automatically alert BCCDC.	

BCCDC contact for questions: TB Services, phone: 604-707-5678 or tbnurseconsultants@bccdc.ca. For Island Health, call 250.519.1510.

5.0 References

BC Centre for Disease Control (BCCDC). TB Manual: Interferon gamma release assay testing guideline for latent tuberculosis infection: Physician guidelines. www.bccdc.ca/resource-gallery/Documents/Communicable-Disease-Manual/Chapter%204%20-%20TB/TB manual IGRA guidelines.pdf (July 2021). Accessed Nov 1, 2022.

BC Centre for Disease Control (BCCDC). (2019). Communicable Disease Control Manual, Chapter 4: Tuberculosis. www.bccdc.ca/health-professionals/clinical-resources/communicable-disease-control-manual/tuberculosis. Accessed Nov 1, 2022.

BC Centre for Disease Control (BCCDC). TB screening decision support tool - Non-certified practice. www.bccdc.ca/resource-gallery/Documents/Communicable-Disease-Manual/Chapter%204%20-%20TB/4.0b%20TB%20Screening%20DST.pdf. Oct 2019. Accessed Nov 1, 2022.

Public Health Agency of Canada, The Lung Association and Canadian Thoracic Society. Canadian Tuberculosis Standards, 7th Edition, 2014. https://cts-sct.ca/wp-content/uploads/2018/01/Canadian-Tuberculosis-Standards 7th-edition Complete.pdf... Accessed Nov 1, 2022.



Ferguson, TW et. al. (2014). The diagnostic accuracy of tests for latent tuberculosis infection in hemodialysis patients: A systematic review and meta-analysis, *Transplantation*, Oct 3 (Epub). http://www.ncbi.nlm.nih.gov/pubmed/25286055. Accessed Nov 1, 2022.

Rogerson, TE et. al. (2013). Tests for latent tuberculosis in people with ESRD: A systematic review. *Am J Kidney Dis*, 61(1): 33-43. http://www.ncbi.nlm.nih.gov/pubmed/23068425. Accessed Nov 1, 2022.

6.0 Sponsors

Original version (2015) developed by:

 A working group of representative groups of renal clinicians and directors/managers, BC laboratories, BCCDC TB Services, Island TB Clinic and BC Renal (BCR)

Original version (2015) approved by:

- BCR Peritoneal Dialysis Committee
- BCR Medical Advisory Committee
- Provincial Committee for Implementation of TB Screening for Dialysis Patients (BCR/BCCDC, BC Public Health Microbiology and Reference Lab)

Update in 2019 reviewed by:

- Representatives from Zoonotic Diseases & Emerging Pathogens Laboratory, BCCDC Public Health Laboratory (Team Lead & Technical Coordinator)
- BCPRA Hemodialysis Committee (Sept 11, 2019 discussed but not reviewed)

In 2022, the 2019 version was adapted and updated to incorporate Kidney Care Clinic (KCC) patients referred for transplant. The 2022 update was completed in collaboration with representatives from the BC Centre for Disease Control, PROMIS Team and the BC Renal Kidney Care, PD and HD Committees.

In 2024, the 2022 version was updated following a review of various details of testing with BCCDC. The changes were summarized in a memo sent out in January 2024.



7.0 Appendices

Appendix 1: TB Screening Workflow for Renal Patients

Appendix 2: TB Screening Questionnaire (printed from PROMIS)

Appendix 3: IGRA Lab Requisition (printed from PROMIS)

Appendix 4: Chest X-Ray Requisition (printed from PROMIS)

Appendix 5: Distribution of Reports/Letters & Follow up of Results


Appendix 6: Samples of Follow- up Reports/Letters for Different Results:

- Letter 1: Non-Reactive IGRA Results
- Letter 2: Reactive IGRA Results (Latent TB infection)



Appendix 1: BC TB Screening Workflow for Renal Patients

This workflow applies to patients starting on dialysis (hemodialysis and peritoneal dialysis and patients attending Kidney Care Clinics referred for transplant.





Appendix 2: TB Screening Questionnaire in PROMIS

- 1. Please complete all sections highlighted in yellow (unless pre-populated with correct information).
- 2. Reason for screening: Provincial Renal TB Screening.

BC Centre for Disease	· Control Pro	ovinci	al Tubercu	ılos	is Sen	/ices	Pr	rovincial For			NG FORM ients, Sept 20:
	NSTRUCTIONS:			_	ILL CLIENT	BIL	LL MSP	X BIL	L TO TB SERVI	CES MSP BIL	LING # 99996
TODAY'S DATE (YYYY/MM/DD) 18-OCT-2022	PERSONAL HE 9868151283	ALTH NUMB	ER (PHN)	1	ID NUMBE	4					
PART 1: CLIENT COMPLETES (use in LAST NAME BELL	nk and print clearly)		GIVEN NAME(8) TEST					MA	IDEN NAME (IF	APPLICABLE)	
FULL ADDRESS 123 MAIN			I			VANCO	UVER	· ·	PROVINCE	POSTAL V6Z1Y6	CODE
DATE OF BIRTH(DOMONTO) 05 MAR 1961	GENDER M X F	ETHNIC OF	RIGIN		STATUS NON-ST		I 🗏 🛚	FIRST NATION NUIT METIS	S FIRST NAT	TONS COMMU	OFF RESERV
COUNTRY OR CANADIAN PROVINCE BRITISH COLUMBIA	E OF BIRTH		DATE ENTERED C		(mmanaco)	PRIMARY PHO (778)000-000		BER	ALTERNAT	TE PHONE NUM	IBER
NAME OF REFERRING PHYSICIAN	SYHEALTH CARE PR	ROVIDER(HO	OP) & SPECIALTY							IMBER OF REF	
NAME OF FAMILY GP SAUNDERS, MARYAM	A CAUDI ETTE								PHONE NI (111)333-	IMBER OF FAN 4444	ILY GP
PART 2: HEALTH CARE PROVIDER OF REASON FOR SCREENING (REFER Renal TB Screening					YES	LERGIES X	NONE		NON	ΙE	OMINISTRATION
IF CONTACT, NAME OF TB CASE O						CONTACTorrow		HISTORIC EXPO	DSURE? IF YES	LIST DETAILS	(NAME, DATE IDE
RISK FACTORS NONE X HIV TRANSPLANT (SPEC				RONIC		ASE/DIALYSIS		ICER (SPECIFY			X DIABETES
TRAVEL TO HIGH PREVALENCE IMMUNE SUPPRESSING MEDICAL IMMUNE SUPPRESSION SUP						SUBSTANCE U	SE		X SETT		
NONE X COUGH X PRO					OTHER	ER WEIGH	HT LOSS	CHEST PA	AIN	YES D	NO
HEPATITIS HISTORY? NONE X HEP B X HEI		PREVIOU	IS BCG?		IF YES	3, DATE(YYYAMA)	00)		CG SCAR?		UNCERTAIN
HAS CLIENT EVER HAD TB?	PREVENTA	TIVE TREAT	MENT? RE	SULT		S TST X U	JNKNOWN			LOCATION	
PROVIDERTUNIE)	ED CONSENT IPTIN, HEALTH CENTRE AND	HINT	DID NOT TE DATE GIVENOVO 18 OCT 2022	ST	DAT 18 O	E READ(************************************	00)	SIZE OF IND	tes	AD BY	
test LOT # FOLLOW-UP RECOMMENDATIONS									MM	negative	positive
X NO FURTHER TESTING R	EPEAT TST IN	WEEKS	SPUTUM FOR A	_	IGRA)	CXR, TYPE	X PA	X LATERAL	X DECLINE	D	
	ED CONSENT IPITAL, HEALTH CHATRE AND	MINT PROVIDER	DATE GIVENOVO 18 OCT 2022	MMCC)		E READ(vvvvaas) CT 2022	00)	SIZE OF INDI 45	MM tes	AD BY	
FOLLOW-UP RECOMMENDATIONS									L	negative	positive
NO FURTHER TESTING HISTORY OF IGRA TEST?		REBULT O	F IGRA?		$\overline{}$	DECLINED		Т	LOCATION		
X QFT T-SPOT		UNK	I-REACTIVE F	REACTI	VE	18 OCT 2022	,				
ALUTTUTAL COMMENTS.											
PART 5: TB SERVICES COMPLETES - RADIOLOGY RESULTS LOCATION OF CXR test DATE OF CXR 18 OCT 2022 CXR ON X CARE CONNECT X 5-FILM SECURE DRIVE WOM OR REPORT ONLY											
LOCATION OF CXR DATE OF CXR 16 OCT 2022 CXR ON X CARE CONNECT X 6-FILM SECURE DRIVE WOMI OR REPORT ONLY PART TO SERVICES COMPLETES - RECOMMENDATIONS											
NO EVIDENCE OF ACTIVE TB	- RECOMMENDATIO					CLINIC APPOIN	ITMENT			DATE & S	IGNATURE
X SEE REPORT			REPEAT TST		- 1	X LTBI OFFE					
TB LETTER (SPECIFY)			IGRA			OTHER (SE	PECIFY) .			24 OCT 202	2
The information collected on this form is information is protected from unauthorize	The information collected on this form is used by the SC Centre for Disease Control to deliver Provincial TB Services. It is collected under the authority of British Columbia,s Public Health Act. Personal information is protected from unauthorized use and disclosure is in accordance with the Freedom of Information and Protection of Privacy Act and may be disclosed only as provided by that Act.										
Powered by PROM	IIS Pri	nted by:	ASOO2			Printed	d on:	31-OCT-20	022 17:55	Pag	e l of



Appendix 3: IGRA Lab Requisition in PROMIS



Public Health Laboratory

Zoonotics Diseases & Emerging Pathogens Requisition



655 West 12th Avenue, Vancouver, BC V5Z 4R4 www.bccdc.ca/publichealthlab

FOR BCCDC TB SERVICES USE ONLY

Insect bite: Skin rash: Rickettsia rickettsia Antibody (Focky Mourtain Spotted Fever) Trichinelia spp. Antibody Trypanosoma cruzi (American trypanosomiasis)	Section 1 - Patient Information (Two match	ing unique patient identifiers on sample container and requ	isition are required for sample processing)
CHEMS ADDRESS CTY POSTAL CODE VANCOUVER VC21V Section 2 - Healthcare Provider Information ADDITIONAL COPIES TO PRACTITIONER(Purish MCC) Nomin and address of report delibery ADAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAPPOINT ADAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAAMS, AGNES(8672), 128 Main, Vancouver, BC, VSGXS6 AAAM			DATE RECEIVED
DOTES NAME VANCOUVER VALVE V	PATIENT SURNAME	PATIENT FIRST AND MIDDLE NAME	
Section 2 - Healthcare Provider Information	CHEN	MAGDALENE	LABORATORY
Section 2 - Healthcare Provider Information ORDERNO PRACTITIONER (Provide MCG) ADDITIONAL COPIES TO PRACTITIONER (CLINIC: (Plant), Additional Copies of report delibro) ADDITIONAL COPIES TO PRACTITIONER (CLINIC: (Plant), Additional Copies of Practitional Copies of Practiti			USE ONLY
OUTBREAK ID SAMPLE REF. NO. DATE COLLECTED COMMANYYYY OUTBREAK ID OUTBREAK ID OUTBREAK ID SAMPLE REF. NO. DATE COLLECTED COMMANYYYY OUTBREAK ID OUTBREAK IN OUTBREAK I			 -
ADAMS_AGNES(8072), 123 Mein, Vancouver, BC, VisG2X6	Section 2 - Healthcare Provider Informati	on	<u> </u>
Approved by Provincial TB Services 1. PROMIS 2. BCCDC TB SERVICES 3. DA VICTORIA COOK TIME COLLECTED (COMMANYYYY) TIME COLLECTED (PACAMIN) TIME WHITCH PACAMIN TIME COLLECTED (PACAMIN) TIME COL	Name and address of report delivery	(Name, Address/MSC#/PHSA Client#) (Limit of 3 conies available)	OUTBREAK ID
Approved by Provincias TE Services do not require a copy of the repot lam a Locum ELocum, include name of Practitioner you are covering for Section 3 - Teat(a) Requested Paratition Section 3 - Teat(a) Requested	ADAMS, AGNES(8672), 123 Mail, Varicouver, BC, VSG.		SAMPLE REF. NO.
It Coum, include name of Practitioner you are covering for It Coum, include name of Practitioner you are covering for It Coum, include name of Practitioner you are covering for It Coum, include name of Practitioner you are covering for It Coum, include name of Practitioner you are covering for It Coum, include name of Practitioner you have a failth only It Coum, include name of Practitioner you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and include you have a failth only It Coum, and you have a failth only	X Approved by Provinicial TB Services		
Electrician Requested Pactitioner you are covering for Pact Pa	I do not require a copy of the report I am a L		
Chikungunya Virus Artibody Dengue Virus Artibody	If Locum, include name of Practitioner you are covering		
Chikungunya Virus Antibody Bartonstin bensalsa Bartonstin be	Section 3 - Test(s) Requested		
Dengue Virus Artibody Bartonelia hansolea Artibody PCR Entamobale histolytica (Amoebiasis) Antibody Schistosoma spp. Antibody Strongyloides spp. Antibody Travel History Required for Above Tests: Codella burnetii (Q-fever) Antibody Travel History Required for Above Tests: Dightheria Antibody PCR Holicobacter pylori Antibody Travel History Required for Above Tests: Puncil Puncil Holicobacter pylori Antibody Travel History Required for Above Tests: Puncil Puncil Holicobacter pylori Antibody Travel History Required for Above Tests: Travel H			PARASITES
Hanta Virus Antibody PCR Chitaronocor restoration required Derreita burgdorfer (Lyme dissesse) Chitaronocor restoration Chita			Echinococcus spp. Antibody
Partial virus Antibody PCR Schistoscoma spp. Antibody Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Strongyloides spp. Antibody Travel History Required for Above Tests: Strongyloides spp. Antibody Strongyloides spp. Antib			Entamoeba histolytica (Amoebiasis) Antibody
West Nile Virus Antibody PCR Borrelia hermsil Antibody PCR Strongyloides spp. Antibody Travel Within past 12 months, specify: Travel History Required for Above Tests: Coxidelia burnetii (Q-fever) Antibody Travel History Required for Above Tests: Indicate prenafal status for Zika virus): Diphtheria Antibody PCR Indicate prenafal status for Zika virus): Diphtheria Antibody PCR Diphtheria Antibody PCR Indicate prenafal status for Zika virus): Diphtheria Antibody PCR Diphtheria Antibody PCR Diphtheria Antibody PCR Diphtheria Antibody PCR Diphtheria Antibody Description De			Schistosoma spp. Antibody
Silva Virus Antibody and PCR Buruella abortus Antibody Brucella abortus Antibody Caxiella burneti (O-fever) Antibody Caxiella burnetii (O-fever) Antibody Travel History Required for Above Tests: (indicate prenatal status for Zika virus): Diphtheria Antibody Helicobacter pylori Antigen (Foces) Legionella sp. Urine Antigen Toxoplasana gondil Antibody Travel Within past 12 months, specify: Toxoplasana gondil Antibody Travel within past 12 months, specify: Travel History Required for Above Tests: (indicate prenatal status for Zika virus): Diphtheria Antibody Helicobacter pylori Antigen (Foces) Legionella sp. Urine Antigen Toxoplasana gondil Antibody Inmune status lgG Acute Infection IgM TripenLocation Tri	_		Strongyloides spp. Antibody
Submit 1 gold top and 1 EDTA blood tube Brucella abortus Antibody Caciella burnetii (0-fever) Antibody Travel Within past 12 months, specify: Www.elabhandbook.info/PHSA/Default.aspx	I -	Borrella hermsii Antibody	
Travel / Clinical History Required for Above Tests: (Indicate prenatal stafus for Zika virus): Prancisella tularensis Antibody		Brucella abortus Antibody	Travel History Required for Above Tests:
Francisella tularensis Antibody Helicobacter pylori Antigen (Feoes) Leishmania spp. Antibody Toxoplasma gondi Antibody Insect bite: Skin rash: Rickettsia rickettsil Antibody (Focky Mountain Spotad Fever) Trichinella spp. Antibody Toxoplasma gondi Antibody Insect bite: Skin rash: Rickettsia rickettsil Antibody (Focky Mountain Spotad Fever) Trichinella spp. Antibody Trypen.coation Trichinella spp. Antibody Trypen.coation Trichinella spp. Antibody Trypen.coation Trypen.coation Tetanus Antiboxin Tetanus Antiboxin Tetanus Antiboxin Tetanus Antiboxin Tetanus Antiboxin Tetanus Antiboxin Treponema cruzi (American trypanosomiasis) Antiboxy Trypenosoma cruzi (American trypanosomiasis) Tetanus Antiboxin Tetanu	Other, specify:	Coxiella burnetii (Q-fever) Antibody	Travel within past 12 months, specify:
Francisella tularensis Antibody Helicobacter pylori Antigen (Feoes) Leistmania spp. Antibody Toxopiasma gondii Antibody To	Travel / Clinical History Required for Above Tests:	Diphtheria Antitoxin	
Helicobacter pylori Antigen (Foces) Leishmania spp. Antibody Capitophrasia Leishmania spp. Antibody Toxoplasma gondii Antibody Immune status IgG Acute Infection IgM Immune status IgG	(indicate prenatal status for Zika virus):	Francisella tularensis Antibody	
Legionella sp. Urine Artigen Leishmania spp. Artibody Toxoplasma gondi Artibody Toxoplasma gondi Artibody PCR Immune status igG Acute Infection igM Trichinella spp. Artibody Trichi		l <u>=</u>	
Signs / Symptoms			Leishmania spp. Antibody
Asymptomatic Antibody PCR Immune status IgG Acute Infection IgM Pickettsia rickettsia Antibody (Pooky Mountain Spotted Fever) Trichinella spp. Antibody Trichinella spp. Antibody Trypan.cocma cruzi (American trypanosomiasis) Trypan.cocma cruzi (American trypanosomiasis) Antibody Trypan.cocma cruzi (American trypanosomiasis) Trypan.cocma cruzi (American trypanosomiasis) Antibody Trypanosoma cruzi (American trypanosomiasis) Trypanosoma cruzi (American trypanosomiasis) Antibody Trypanosoma cruzi (American trypanosomiasis) Trypanosoma cruzi (American trypanosomia	Signs / Symptoms		Toxoplasma gondii Antibody
Type/Location	Asymptomatic		Immune status IgG Acute Infection IgM
Neurological X OFT Gold Plus T Spot Antibody Other, specify: T B IGRA TESTING CRITERIA 1. TST negative, immunocompromised 1. TST negative, immunocompromised 2. TST positive, BCG positive Coccidioides sp. Antibody 2. TST positive, BCG positive Cryptococcus neoformans Antigen 3. TST positive, indegenous / Foreign born 4. Dialysis patilent 5. CKD direct transplant 5. CKD direct transplant 6. SOT and L/BMT patient Travel History Required for Above Tests: For other svaliable tests and additional information, consult the Public Health Laboratory's eLab Handbook at www.elabhandbook.info/PHSA/Default.aspx	Insect bite: Skin rash:	Plickettsia rickettsii Antibody (Rocky Mountain Spotled Fever)	Trichinella spp. Antibody
Neurological X OFT Gold Plus T Spot	Type/Location	X TB Interferon Gamma Release Assay*	Trypanosoma cruzi (American trypanosomiasis)
SYPHILIS VDRL (CSF sample only) Submit 1 mL CSF in sterile leak-proof tube Disastomyces dermatidis Antibody 1. TST negative, Immunocompromised 2. TST positive, BCG positive Coccidioides sp. Antibody 2. TST positive, BCG positive Cryptococcus neoformans Antigen 3. TST positive, Indegenous / Foreign born 4. Disalysis patilent 4. Disalysis patilent 5. CKD direct transplant 5. CKD direct transplant 6. SOT and L/BMT patient	Neurological	X QFT Gold Plus T Spot	Antibody
VDRL (CSF sample only) □ In ST negative, immunocompromised Submit 1 mL CSF in sterile leak-proof tube □ Coccidioides sp. Antibody □ 2. TST positive, BCG positive □ Treponema pallidum Nucleic Acid Testing* □ Cryptococcus neoformans Antigen □ 3. TST positive, indegenous / Foreign born □ Darkfield (DF) Microscopy □ Other, specify: □ 5. CKD direct transplant □ Direct Fluorescent Assay (DFA) Microscopy □ Other, specify: □ 6. SOT and L/BMT patient □ Signs / Symptoms □ Asymptomatic □ Rash □ Travel History Required for Above Tests: For other available tests and additional information, consult the Public Health Laboratory's eLab Handbook at Www.elabhandbook.info/PHSA/Default.aspx	Other, specify:	Tetanus Antitoxin	Other, specify:
Darkfield (DF) Microscopy Source of sample: Direct Fluorescent Assay (DFA) Microscopy Source of sample: Travel History Required for Above Tests: Travel within past 12 months, specify: Www.elabhandbook.info/PHSA/Default.aspx	SYPHILIS	FUNGI	* TB IGRA TESTING CRITERIA
Submit 1 mL CSF in sterile leak-proof tube Cocidioides sp. Antibody 2. TST positive, BCG positive Treponema pallidum Nucleic Acid Testing* Cryptococcus neoformans Antigen 3. TST positive, Indegenous / Foreign born Darkfield (DF) Microscopy Other, specify: 5. CKD direct transplant Direct Fluorescent Assay (DFA) Microscopy Other, specify: 5. SOT and LIBMT patient Travel History Required for Above Tests: For other evailable tests and additional information, consult the Public Health Laboratory's eLab History Required for Above Tests: For other evailable tests and additional information, consult the Public Health Laboratory's eLab History Required for Above Tests: For other evailable tests and additional information, consult the Public Health Laboratory's eLab History Required for Above Tests: For other evailable tests and additional information, consult the Public Health Laboratory's eLab Handbook Airfo/PHSA/Default.aspx Www.elabhandbook.info/PHSA/Default.aspx	VDBI (CSE sample only)	Risetomynes dermatidis Antihody	1. TST negative, immunocompromised
Treponema pellidum Nucleic Acid Testing* Submit exudate, tissue or body fluid Darkfield (DF) Microscopy Source of sample: Direct Fluorescent Assay (DFA) Microscopy Source of sample: Travel History Required for Above Tests: Signs / Symptoms Asymptomatic Rash Other, specify: Signs / Symptomatic Rash Othe			2. TST positive, BCG positive
Darkfield (DF) Microscopy Source of sample: Direct Fluorescent Assay (DFA) Microscopy Source of sample: Travel History Required for Above Tests: Signs / Symptoms Asymptomatic Rash Other, specify: Travel within past 12 months, specify: Www.elabhandbook.info/PHSA/Default.aspx	Treponema pallidum Nucleic Acid Testing*		3. TST positive, Indegenous / Foreign born
Direct Fluorescent Assay (DFA) Microscopy Other, specify: S. CKD direct transplant S. S. S. CKD direct transplant S.	Submit exudate, tissue or body fluid		4. Dialysis patient
Direct Fluorescent Assay (DFA) Microscopy Source of sample: Travel History Required for Above Tests: Signs / Symptoms Asymptomatic Rash Other, specify: Other, specify: 6. SOT and L/BMT patient For other available tests and additional information, consult the Public Health Laboratory's eLab Handbook at www.elabhandbook.info/PHSA/Default.aspx		l <u>=</u>	
Source of sample: Travel History Required for Above Tests: For other available tests and additional information, consult the Public Health Laboratory's eLab Handbook at Www.elabhandbook.info/PHSA/Default.aspx	_		6. SOT and L/BMT patient
Signs / Symptoms Asymptomatic Rash Travel within past 12 months, specify: Handbook at www.elabhandbook.info/PHSA/Default.aspx		Travel History Required for Above Tests:	
Other, specify: www.elabhandbook.info/PHSA/Default.aspx	Signs / Symptoms	Travel within past 12 months, specify:	

Printed on: 25-OCT-2022 03:58



Printed by: KRITHIKAU

Page 1 of 3



Appendix 4: Chest X-Ray Requisition in PROMIS

MSP billing number: 99996



Chest X-Ray Requisition


Chest A-Ray Requisition					
Patient Information	Date 02-NOV-2022				
	Ordering Physician:				
Name: CHEN, MAGDALENE DOB: 27-JAN-1953	ADAMS, AGNES - 8672				
PHN: _9870983905 Phone: _250-585-8596	Vancouver Hospital And H.S.C.				
Address: 123 MAIN, VANCOUVER, BC, V6Z1Y6	Hemodialysis Unit				
	Additional Copies to:				
	BCCDC TB Services, Dr Victoria Cook				
Chest X-Ray Exam Reason					
Exam Requested: Chest					
·	specify:				
Exam Reason:					
□ TB Contact					
☐ TB Screening					
Rule Out Active TB Symptoms					
Repeat CXR					
	Surveillance				
☐ Active ☐ Active	□ Immigration				
□ Latent □ Latent	Other, Specify:				
Respiratory Precautions Required: YES NO					
For Radiology Use Only					
BC CENTRE FOR DISEASE CONTROL TUBERCULOSIS	SERVICES				
655 West 12th Avenue					
Vancouver, BC V5Z 4R4					
70L 111					
IF PHN NOT VALID					
Bill Client					
□ Invoice TB Services					
BC Cestre for Disease Control Fuel National Health Authority fracerhealth interior Health island	health Vancouver Coastal Health				



Page 1 of 3



Appendix 5: Distribution of Reports/Letters & Follow Up of Results



incidental findings: When the ordering provider is from TBS and the chest x-ray has abnormal findings non-related to TB. The physician narrative is completed and a copy of the chest x-ray report will be forwarded to the GP for clinical follow up and nephrologist for clinical context.



Appendix 6: Samples of Follow-Up Reports/Letters

Letter 1: Non-Reactive IGRA Results



TB Screening for this patient was completed.

From the information provided, there is no evidence of TB exposure, infection or disease.

This patient is cleared for TB screening purposes. If the TB Screening Form was initiated prior to immune-suppressing treatments or transplant, these treatments may proceed without delay. Please note that IGRA screening is not required if changing to a new biological product, if changing dose or if adding supplementary agents.

Further testing or treatment for TB infection is not recommended at this time.

Reassessment would be in accordance with disease specific protocols, if symptoms develop or at the discretion of a physician.

Letter 1 (SD2)



Letter 2: Reactive IGRA Results (Latent TB Infection)

This letter applies to Lower Mainland Patients only.

		Clinical Prevention Services Provincial Tuberculosis Services				
	BC Centre for Disease Control Produced adduth Services Aucherity	Vancouver 855 West 12™ Avenue Vancouver, B.C. Canada, V5Z 4R4 Tel # (604) 707-2692 Fax # (604) 707-2690	New Westminster #100 – 237 East Columbia Street New Westminster, B.C. Canada, V3L 3W4 Tel # (804) 707-2898 Fax # (804) 707-2894			
Month I	Day, Year					
Attn c/o	Pt Full Name Pt Address					
Re	Appointment					
Dear Pt	First Name:					
	ng tests show that you <i>may</i> have sleeping o ce to talk to you about options for keeping	마음 교육 경우 이 시간을 가능하고 있다면 하는 사람들이 되었다. 그 사람들은 사람들이 되었다. 사람들이 없는	. This is called latent TB infection (LTBI).			
	n more, please read the LTBI fact sheet (end Korean, Mandarin, Punjabi, Tagalog and V	50 BB - 10 BB -	eo www.bccdc.ca/TBVideos (available in			
Your ap	pointment is on Appt Date at Appt Time					
100 237 NEW W	VESTMINSTER TB CLINIC 7 EAST COLUMBIA VESTMINSTER, BC V3L 3W4 07-2698					
Please r	note that this appointment is by:					
	Video					
	Telephone (Please call our clinic to confirm	your phone number before your a	appointment)			
	In person (Please come 15 minutes early to	check-in)				
If you w	vould like to talk to us another time, please	call us at the number above.				
Sincerel TB Servi	**					
	ial TB Services, Clinical Prevention Services tre for Disease Control					
SL1e To learn	n more about tuberculosis (TB), please wat:	ch the TB germ video www.bccdc.c	ca/TBVideos (available in English, Korean.			
	rin, Punjabi, Tagalog and Vietnamese).					
E ST	Provincial Health Services Authority Province-wide solutions. Better health.	(3	A research and teaching centre attitioned with UBC			